Latest Insider Transactions at Apellis Pharmaceuticals, Inc. (APLS)
This section provides a real-time view of insider transactions for Apellis Pharmaceuticals, Inc. (APLS). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Apellis Pharmaceuticals, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Apellis Pharmaceuticals, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 04
2022
|
Lukas Scheibler Chief Research Officer |
SELL
Open market or private sale
|
Direct |
3,504
-2.14%
|
$196,224
$56.83 P/Share
|
|
Apr 04
2022
|
Lukas Scheibler Chief Research Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,504
+5.91%
|
$45,552
$13.85 P/Share
|
|
Apr 01
2022
|
Lukas Scheibler Chief Research Officer |
SELL
Open market or private sale
|
Direct |
11,496
-18.04%
|
$632,280
$55.05 P/Share
|
|
Apr 01
2022
|
Lukas Scheibler Chief Research Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
11,496
+15.28%
|
$149,448
$13.85 P/Share
|
|
Mar 25
2022
|
Victoria L. Brown Program Team Lead |
SELL
Payment of exercise price or tax liability
|
Direct |
82
-0.29%
|
$4,018
$49.28 P/Share
|
|
Mar 15
2022
|
Federico Grossi Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
375
-0.32%
|
$14,625
$39.57 P/Share
|
|
Mar 15
2022
|
Federico Grossi Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,000
+5.65%
|
$28,000
$4.31 P/Share
|
|
Mar 15
2022
|
Alec Machiels Director |
SELL
Open market or private sale
|
Direct |
1,250
-0.48%
|
$48,750
$39.57 P/Share
|
|
Mar 15
2022
|
Alec Machiels Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,250
+0.48%
|
$2,500
$2.67 P/Share
|
|
Mar 01
2022
|
Federico Grossi Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
375
-0.34%
|
$16,125
$43.53 P/Share
|
|
Feb 23
2022
|
Federico Grossi Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,100
+3.59%
|
$16,400
$4.31 P/Share
|
|
Feb 15
2022
|
Alec Machiels Director |
SELL
Open market or private sale
|
Direct |
1,250
-0.19%
|
$56,250
$45.43 P/Share
|
|
Feb 15
2022
|
Alec Machiels Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,250
+0.18%
|
$2,500
$2.67 P/Share
|
|
Feb 15
2022
|
Federico Grossi Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
375
-0.35%
|
$16,875
$45.43 P/Share
|
|
Feb 14
2022
|
Lukas Scheibler Chief Research Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
720
+1.36%
|
$18,720
$26.73 P/Share
|
|
Feb 14
2022
|
Federico Grossi Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,600
+3.27%
|
$14,400
$4.31 P/Share
|
|
Feb 11
2022
|
Lukas Scheibler Chief Research Officer |
SELL
Open market or private sale
|
Direct |
1,666
-3.13%
|
$76,636
$46.8 P/Share
|
|
Feb 10
2022
|
Mark Jeffrey De Long Chief Business & Strat Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,901
+14.68%
|
-
|
|
Feb 10
2022
|
Mark Jeffrey De Long Chief Business & Strat Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
271
-1.14%
|
$12,737
$47.12 P/Share
|
|
Feb 10
2022
|
Lukas Scheibler Chief Research Officer |
SELL
Open market or private sale
|
Direct |
10,000
-15.83%
|
$500,000
$50.0 P/Share
|
|
Feb 10
2022
|
Lukas Scheibler Chief Research Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+13.67%
|
$130,000
$13.85 P/Share
|
|
Feb 10
2022
|
Lukas Scheibler Chief Research Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
678
-1.26%
|
$31,866
$47.12 P/Share
|
|
Feb 10
2022
|
Victoria L. Brown Program Team Lead |
SELL
Payment of exercise price or tax liability
|
Direct |
175
-0.61%
|
$8,225
$47.12 P/Share
|
|
Feb 10
2022
|
Timothy Eugene Sullivan Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
875
-0.84%
|
$41,125
$47.12 P/Share
|
|
Feb 10
2022
|
Federico Grossi Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
705
-0.68%
|
$33,135
$47.12 P/Share
|
|
Feb 10
2022
|
Adam J. Townsend Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
895
-1.99%
|
$42,065
$47.12 P/Share
|
|
Feb 10
2022
|
Pascal Deschatelets Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,057
-0.12%
|
$49,679
$47.12 P/Share
|
|
Feb 10
2022
|
Cedric Francois Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,523
-0.26%
|
$118,581
$47.12 P/Share
|
|
Feb 10
2022
|
David O. Watson General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
491
-0.37%
|
$23,077
$47.12 P/Share
|
|
Feb 08
2022
|
Lukas Scheibler Chief Research Officer |
SELL
Open market or private sale
|
Direct |
10,000
-15.66%
|
$450,000
$45.0 P/Share
|
|
Feb 08
2022
|
Lukas Scheibler Chief Research Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+13.54%
|
$130,000
$13.85 P/Share
|
|
Feb 01
2022
|
Federico Grossi Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
375
-0.36%
|
$15,000
$40.58 P/Share
|
|
Jan 31
2022
|
Lukas Scheibler Chief Research Officer |
SELL
Open market or private sale
|
Direct |
1,233
-2.24%
|
$46,854
$38.47 P/Share
|
|
Jan 28
2022
|
Lukas Scheibler Chief Research Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
642
-1.15%
|
$24,396
$38.59 P/Share
|
|
Jan 28
2022
|
Karen Lewis Chief People Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
434
-1.82%
|
$16,492
$38.59 P/Share
|
|
Jan 28
2022
|
Cedric Francois Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,024
-0.15%
|
$76,912
$38.59 P/Share
|
|
Jan 28
2022
|
Pascal Deschatelets Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
931
-0.1%
|
$35,378
$38.59 P/Share
|
|
Jan 28
2022
|
Adam J. Townsend Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
800
-1.75%
|
$30,400
$38.59 P/Share
|
|
Jan 28
2022
|
David O. Watson General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
650
-0.49%
|
$24,700
$38.59 P/Share
|
|
Jan 28
2022
|
Timothy Eugene Sullivan Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
650
-0.62%
|
$24,700
$38.59 P/Share
|
|
Jan 28
2022
|
Nur Nicholson Chief Technical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
650
-1.8%
|
$24,700
$38.59 P/Share
|
|
Jan 28
2022
|
Federico Grossi Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
650
-0.62%
|
$24,700
$38.59 P/Share
|
|
Jan 28
2022
|
Jeffrey Eisele Chief Development Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
434
-1.3%
|
$16,492
$38.59 P/Share
|
|
Jan 28
2022
|
Mark Jeffrey De Long Chief Business & Strat Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
434
-2.07%
|
$16,492
$38.59 P/Share
|
|
Jan 28
2022
|
Victoria L. Brown Program Team Lead |
SELL
Payment of exercise price or tax liability
|
Direct |
434
-1.5%
|
$16,492
$38.59 P/Share
|
|
Jan 21
2022
|
James George Chopas VP/Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,974
+31.09%
|
-
|
|
Jan 21
2022
|
Mark Jeffrey De Long Chief Business & Strat Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,592
+33.57%
|
-
|
|
Jan 21
2022
|
Victoria L. Brown Program Team Lead |
BUY
Grant, award, or other acquisition
|
Direct |
17,466
+37.58%
|
-
|
|
Jan 21
2022
|
Karen Lewis Chief People Officer |
BUY
Grant, award, or other acquisition
|
Direct |
17,466
+42.21%
|
-
|
|
Jan 21
2022
|
David O. Watson General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
26,051
+16.32%
|
-
|